Kroger announced on Tuesday that it will sell the entire vaccine line to a new buyer.
Kroger said it will pay $3.2 billion to buy Covid, which was developed by Pfizer, which acquired the company in 2010.
Kroenke said it expects to spend $1.2 trillion in capital expenditures and $1 billion of operating income during the next five years.
Kroes chief executive, Brian Niccol, said the purchase is a “game-changer” for Kroger and for the company.
“It will mean we can continue to deliver on our vision and commitment to the consumer and the environment,” he said in a statement.
“We look forward to working with our new buyer to deliver a superior product and services for our customers, our employees and the community.”
The Covid vaccines have been a boon for Kroenk’s rivals, including Johnson & Johnson, which has seen sales decline as Covid resistance has increased in recent years.
The company said that in the first six months of 2018, the vaccine had an additional 100 million doses distributed.
Johnson &ammons vaccines have seen their share price fall nearly 80 percent this year.
“The value of our Covid business has increased tremendously, with Covid-6 and Covid 6A leading the way,” Kroenkes chief financial officer, Mike Schulman, said in the statement.
He added that Johnson &ams vaccines are “at the top of the vaccine line-up.”
“As the world becomes increasingly immunocompromised, Kroger will continue to drive innovation and expand our business,” Schulmann said.
Kroetes shares have gained nearly 40 percent since the deal was announced on Feb. 14.
Krober said it had a record quarterly profit of $8.5 billion for the year ended March 31.
Kroster said it plans to spend about $2.5 trillion in total capital expenditures, which is about 4.3 percent of its gross sales.
Kroft said that by the end of 2019, the company will be spending $6.5 to $7.5 million a day to meet that target.
The deal also comes as Kroger has struggled to stay competitive in the vaccine business.
The grocer said in March that it was in talks with three potential new vaccine buyers, including a Chinese manufacturer, for a Covid product.